Lundbeck Patent-Cliff Exposure & CMS Drug Spending Portfolio

Lundbeck (US): 2 reconciled FDA prescription therapies, $216.5M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$216.5M
2024 Medicare Part D Spend$46.6M
2024 Medicaid Spend$169.8M
California HCAI SB 17 Filings10 WAC filings (max 26.1% 2-yr change)